Cowen expects NuVasive to maintain momentum this year

NuVasive

05/05/2022 11:09

** Cowen says better-than-expected Q1 results along with
stronger contributions from new product launches should help
specialty surgical products maker  NUVA.O  maintain its momentum
throughout 2022
    ** NUVA reported Q1 adj. EPS of $0.54 vs estimates of $0.39,
and revenue of $290.8 mln beat expectation of $278.0 mln -
Refinitiv data
    ** Co raised lower end of FY 2022 revenue forecast range
    ** At least three brokerages raised PT
    ** Cowen says investors will appreciate Q1 results as they
imply NUVA took share in U.S. spine market
    ** San Diego-based NuVasive, which designs and develops
medical devices for spine disorders, has a market value of about
$2.93 bln - Refinitiv data
    ** Stock was up ~7.3% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))